Collegeville, PA, United States of America

Joelle Lorraine Burgess

USPTO Granted Patents = 18 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 128(Granted Patents)

Location History:

Phoenixville, PA (US) (2001 - 2002)
Trappe, PA (US) (2006)
King of Prussia, PA (US) (2009)
Collegevile, PA (US) (2017)
Collegeville, PA (US) (2002 - 2019)

Company Filing History:

Smithkline Beecham Corporation

patents

3 out of 95

Glaxosmithkline Intellectual Property (no.2) Limited

patents

4. 1 out of 93

Nps Pharmaceuticals, Inc.

patents

5. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2019

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10478426 - Enhancer of Zeste Homolog 2 inhibitors (2019-11-19),

2. 9956210 - Enhancer of zeste homolog 2 inhibitors (2018-05-01),

3. 9790212 - Enhancer of zeste homolog 2 inhibitors (2017-10-17),

4. 9562041 - Enhancer of zeste homolog 2 inhibitors (2017-02-07),

5. 9556157 - Enhancer of zeste homolog 2 inhibitors (2017-01-31),

6. 9505745 - Enhancer of zeste homolog 2 inhibitors (2016-11-29),

7. 9402836 - Indoles (2016-08-02),

8. 9073924 - Azaindazoles (2015-07-07),

9. 8975291 - Indoles (2015-03-10),

10. 8637509 - Azaindazoles (2014-01-28),

11. 8404837 - Quinoline derivatives as P13 kinase inhibitors (2013-03-26),

12. 7482455 - Chemical compounds (2009-01-27),

13. 7166639 - NF-κB inhibitors (2007-01-23),

14. 7109238 - Calcilytic compounds (2006-09-19),

15. 7087758 - Quinoline inhibitors of hyaki and hyak3 kinases (2006-08-08),

Title: The Innovative Journey of Joelle Lorraine Burgess: A Pioneer in Cancer Therapy

Introduction: Joelle Lorraine Burgess, based in Collegeville, PA, is a remarkable inventor known for her significant contributions to the field of cancer therapeutics. With a total of 18 patents to her name, Joelle has made substantial strides in developing innovative solutions for the treatment of various cancers.

Latest Patents: Among her latest inventions are the "Enhancer of Zeste Homolog 2 inhibitors." This groundbreaking patent details novel substituted benzamides, which function as inhibitors of the Enhancer of Zeste Homolog 2 (EZH2). These compounds are pivotal in pharmaceutical compositions, offering new therapeutic options for cancer treatment. The detailed processes for their preparation further underscore the potential impact of her inventions on modern medicine.

Career Highlights: Throughout her career, Joelle has excelled in advancing research and development initiatives in the pharmaceutical industry. Notable companies she has been associated with include GlaxoSmithKline LLC and SmithKline Beecham Corporation. Her work has consistently aimed at harnessing the power of innovative chemistry to address critical healthcare challenges.

Collaborations: Joelle has worked alongside esteemed colleagues such as Steven David Knight and James Francis Callahan. These collaborations not only reflect her ability to foster synergistic relationships but also emphasize her commitment to advancing science through teamwork and shared expertise.

Conclusion: Joelle Lorraine Burgess stands as a testament to the power of innovation in the fight against cancer. Her extensive patent portfolio and collaborative efforts highlight her influential role as an inventor and researcher. As therapies continue to evolve, her contributions will undoubtedly pave the way for improved treatment options and advancements in cancer research.

This text is generated by artificial intelligence and may not be accurate.